• Mario Habek, Ivan Adamec, Barbara Barun, Vanja Bašić Kes, Andrijana Bogoje Raspopović, Duka GlavorKlaudiaK, Tereza Gabelić, Tihana Grzinčić, Mirjam Jukić, Miljenka-Jelena Jurašić, Spomenka Kiđemet-Piskač, Milica Komšo, Julija Rimac, Ines Lazibat, Branka Lukić, Anita Marčinko, Meri Matijaca, Marija Ratković, Lidija Šapina, Vladimira Vuletić, Tea Mirošević Zubonja, and Magdalena Krbot Skorić.
• Mario Habek, University Hospital Center Zagreb, Department of Neurology, Kišpatićeva 12, 10000 Zagreb, Croatia, mario.habek@mef.hr.
• Croat. Med. J. 2022 Aug 31; 63 (4): 379-388.

AbstractUntreated multiple sclerosis (MS) irretrievably leads to severe neurological impairment. In European health care systems, patient access to disease modifying therapies (DMT) is often confined to more advanced stages of the disease because of restrictions in reimbursement. A discrepancy in access to DMTs is evident between West and East European countries. In order to improve access to DMTs for people with MS (pwMS) living in Croatia, the Croatian Neurological Society issued new recommendations for the treatment of relapsing MS. The aim of this article is to present these recommendations. The recommendations for platform therapies are to start DMT as soon as the diagnosis is made. If poor prognostic criteria are present (≥9 T2 or FLAIR lesions on the initial brain and spinal cord magnetic resonance imaging [MRI] or ≥3 T1 lesions with postcontrast enhancement on the initial brain and spinal cord MRI or Expanded Disability Status Scale after treatment of the initial relapse ≥3), high-efficacy DMT should be initiated. If pwMS experience ≥1 relapse or ≥3 new T2 lesions while on platform therapies, they should be switched to high-efficacy DMT. Further efforts should be made to enable early and unrestricted access to high-efficacy DMT with a freedom of choice of an appropriate therapy for expert physicians and pwMS. The improvement of access to DMT achieved by the implementation of national treatment guidelines in Croatia can serve as an example to national neurological societies from other Eastern European countries to persuade payers to enable early and unrestricted treatment of pwMS.

19 keywords...

hide…